Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

PTCT

PTC Therapeutics Inc

Jan 09 • 04:00PM ET

77.53

+0.68 0.88 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: IJR VTI VB IWM XBI VBK VXF SPSM IJT IBB

Scroll to Statements

Index	RUT	P/E	9.06	EPS (ttm)	8.56	Insider Own	3.89%	Shs Outstand	79.93M	Perf Week	1.03%
Market Cap	6.17B	Forward P/E	-	EPS next Y	-1.20	Insider Trans	-14.88%	Shs Float	76.95M	Perf Month	5.53%
Enterprise Value	4.89B	PEG	-	EPS next Q	-0.28	Inst Own	103.03%	Short Float	14.87%	Perf Quarter	17.45%
Income	751.72M	P/S	3.47	EPS this Y	301.16%	Inst Trans	11.58%	Short Ratio	7.46	Perf Half Y	59.69%
Sales	1.78B	P/B	-	EPS next Y	-112.59%	ROA	33.51%	Short Interest	11.44M	Perf YTD	2.07%
Book/sh	-1.95	P/C	3.66	EPS next 5Y	-	ROE	-	52W High	87.50 -11.39%	Perf Year	73.80%
Cash/sh	21.21	P/FCF	8.75	EPS past 3/5Y	14.01% -2.04%	ROIC	-	52W Low	35.95 115.66%	Perf 3Y	96.28%
Dividend Est.	-	EV/EBITDA	5.12	Sales past 3/5Y	14.42% 21.32%	Gross Margin	95.78%	Volatility	3.34% 2.87%	Perf 5Y	28.15%
Dividend TTM	-	EV/Sales	2.75	EPS Y/Y TTM	261.84%	Oper. Margin	51.84%	ATR (14)	2.45	Perf 10Y	137.17%
Dividend Ex-Date	-	Quick Ratio	2.26	Sales Y/Y TTM	97.54%	Profit Margin	42.25%	RSI (14)	54.08	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	114.06%	SMA20	0.95%	Beta	0.48	Target Price	82.43
Payout	-	Debt/Eq	-	Sales Q/Q	7.23%	SMA50	2.18%	Rel Volume	1.02	Prev Close	76.85
Employees	939	LT Debt/Eq	-	Earnings	Nov 04 AMC	SMA200	33.61%	Avg Volume	1.53M	Price	77.53
IPO	Jun 20, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	117.65% 22.04%	Trades		Volume	1,567,051	Change	0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$91
Oct-20-25	Initiated	Wells Fargo	Overweight	$73
Jun-17-25	Initiated	Truist	Buy	$80
May-09-25	Upgrade	BofA Securities	Neutral → Buy	$68
May-07-25	Upgrade	Citigroup	Sell → Neutral	$40
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral	$41 → $55
Mar-07-25	Initiated	Scotiabank	Sector Perform	$55
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform

Show Previous Ratings

Jan-08-26 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-22-25 07:00AM	PTC Therapeutics Announces Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan (PR Newswire)
Dec-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.34%
Dec-18-25 08:00AM	PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.90%
09:46AM	Loading…
09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 06:06PM	SanDisk stock surges after S&P 500 inclusion announcement (Investing.com)
06:01PM	Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 (PR Newswire)
Nov-20-25 08:00AM	PTC Therapeutics to Host R&D Day (PR Newswire)
Nov-05-25 12:02AM	PTC Therapeutics Inc (PTCT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.98%
Nov-04-25 06:00PM	Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics (Zacks)
05:25PM	PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates (Zacks)
04:21PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 07:24AM	What To Expect From PTC Therapeutics Inc (PTCT) Q3 2025 Earnings (GuruFocus.com)
08:00AM	Loading…
Oct-31-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Oct-30-25 05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 12:24PM	Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 (Insider Monkey)
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-21-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results (PR Newswire)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
Oct-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-11-25 11:15AM	PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU (Insider Monkey)
Sep-05-25 08:35AM	Here's Why Shares in PTC Therapeutics Soared This Week (Motley Fool)
Sep-03-25 02:03PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily) +5.95%
Aug-29-25 04:52AM	PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich's Ataxia (Insider Monkey)
Aug-21-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
10:35AM	Loading…
10:35AM	PTC Therapeutics CRL expected, focus moves to Sephience, says RBC Capital (TipRanks)
Aug-19-25 08:00AM	PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA (PR Newswire)
07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-07-25 06:00PM	PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -9.89%
05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:25PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
08:00AM	Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE (sepiapterin) (PR Newswire)
Jul-28-25 04:19PM	PTC Therapeutics Announces FDA Approval of Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire) +11.16%
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-21-25 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results (PR Newswire)
Jul-09-25 09:36AM	Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Jun-23-25 07:00AM	Sephience (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Jun-19-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-06-25 12:00PM	All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy (Zacks)
May-10-25 10:35AM	PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 05:02AM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +12.63%
03:20AM	PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 11:19PM	PTC Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
04:01PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (PR Newswire)
11:03AM	PTC Therapeutics price target lowered to $57 from $65 at RBC Capital (TipRanks)
May-05-25 04:54PM	Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? (Benzinga) -18.62%
09:29AM	Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result (GuruFocus.com)
08:22AM	PTC stock slides on new data for Huntingtons drug (BioPharma Dive)
07:00AM	PTC518 PIVOT-HD Study Achieves Primary Endpoint (PR Newswire)
May-01-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-25 09:00AM	PTC Therapeutics Receives Positive CHMP Opinion for Sephience (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) (PR Newswire)
Apr-24-25 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Apr-21-25 07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-17-25 10:01AM	PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results (PR Newswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.56%
Mar-28-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.05%
09:00AM	PTC Therapeutics Provides Regulatory Update on Translarna (ataluren) in Europe (PR Newswire)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-20-25 08:00AM	PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies (PR Newswire)
Feb-28-25 11:41AM	Q4 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.27%
02:35AM	PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
Feb-27-25 05:30PM	PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:17PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-26-25 07:21AM	PTC Therapeutics Inc (PTCT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 09:16AM	Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-19-25 07:00AM	PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia (PR Newswire)
Feb-13-25 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-04-25 08:21AM	PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald (TipRanks)
05:01AM	PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? (Zacks)
Feb-03-25 03:07PM	Why PTC Therapeutics (PTCT) Stock Is Rallying Today (Insider Monkey) +9.00%
Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
Dec-04-24 07:15AM	PTC Therapeutics price target raised to $71 from $47 at UBS (TipRanks)
Dec-03-24 04:42AM	Novartis and PTC Therapeutics link to develop Huntingtons therapy (Pharmaceutical Technology)
Dec-02-24 04:21PM	PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone (Investor's Business Daily) +18.66%
12:58PM	PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program (Benzinga)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boulding Mark Elliott	Officer	Jan 09 '26	Proposed Sale	77.92	2,314	180,314		Jan 09 04:11 PM
Pauwels Eric	Officer	Jan 09 '26	Proposed Sale	77.89	2,746	213,889		Jan 09 04:09 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 06 '26	Sale	76.95	1,381	106,268	74,962	Jan 08 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '26	Sale	77.45	1,235	95,651	73,727	Jan 08 05:20 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jan 06 '26	Sale	76.95	2,139	164,596	90,310	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 06 '26	Sale	76.95	1,789	137,664	88,841	Jan 08 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 07 '26	Sale	77.48	1,352	104,753	87,489	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 06 '26	Sale	76.95	5,149	396,216	399,983	Jan 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '26	Sale	77.48	3,016	233,680	396,967	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	76.95	1,340	103,113	93,936	Jan 08 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '26	Sale	77.48	642	49,742	93,294	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Option Exercise	38.10	3,376	128,626	120,284	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '26	Sale	77.44	4,879	377,825	117,659	Jan 08 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 06 '26	Sale	76.95	1,739	133,816	119,162	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	1,279	98,419	117,103	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	1,026	79,494	116,077	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 06 '26	Sale	76.95	54	4,155	6,902	Jan 08 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '26	Sale	77.48	52	4,029	6,850	Jan 08 05:20 PM
Golden Lee Scott	Officer	Jan 08 '26	Proposed Sale	76.45	866	66,205		Jan 08 04:45 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.53	3,148	240,905		Jan 08 04:37 PM
Klein Matthew B.	Officer	Jan 08 '26	Proposed Sale	76.45	2,514	192,193		Jan 08 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 08 '26	Proposed Sale	76.45	59	4,510		Jan 08 04:29 PM
Almstead Neil Gregory	Officer	Jan 08 '26	Proposed Sale	76.45	881	67,352		Jan 08 04:27 PM
Pauwels Eric	Officer	Jan 08 '26	Proposed Sale	76.45	1,454	111,157		Jan 08 04:24 PM
Utter Christine Marie	Officer	Jan 08 '26	Proposed Sale	76.45	1,034	79,048		Jan 08 04:22 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.45	1,286	98,314		Jan 08 04:17 PM
Boulding Mark Elliott	Officer	Jan 08 '26	Proposed Sale	76.61	2,747	210,448		Jan 08 04:10 PM
Klein Matthew B.	Officer	Jan 07 '26	Proposed Sale	77.48	3,016	233,691		Jan 07 04:38 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.42	3,376	261,382		Jan 07 04:37 PM
Golden Lee Scott	Officer	Jan 07 '26	Proposed Sale	77.48	642	49,745		Jan 07 04:37 PM
Boulding Mark Elliott	Officer	Jan 07 '26	Proposed Sale	77.48	1,503	116,458		Jan 07 04:36 PM
Utter Christine Marie	Officer	Jan 07 '26	Proposed Sale	77.48	1,235	95,692		Jan 07 04:36 PM
Almstead Zheng Yang	Member of immediate family of	Jan 07 '26	Proposed Sale	77.48	52	4,029		Jan 07 04:21 PM
Pauwels Eric	Officer	Jan 07 '26	Proposed Sale	77.48	1,352	104,758		Jan 07 04:17 PM
Almstead Neil Gregory	Officer	Jan 07 '26	Proposed Sale	77.48	1,026	79,498		Jan 07 04:14 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Option Exercise	39.42	2,266	89,326	123,167	Jan 06 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 05 '26	Sale	75.55	2,266	171,192	120,901	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Option Exercise	46.54	734	34,160	11,400	Jan 06 05:20 PM
Reeve Emma	Director	Jan 05 '26	Sale	76.00	734	55,784	10,666	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Option Exercise	30.86	12,000	370,320	30,500	Jan 06 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Sale	76.35	12,000	916,200	18,500	Jan 06 05:20 PM
Klein Matthew B.	Officer	Jan 06 '26	Proposed Sale	76.95	5,149	396,203		Jan 06 04:46 PM
Utter Christine Marie	Officer	Jan 06 '26	Proposed Sale	76.95	1,381	106,265		Jan 06 04:42 PM
Golden Lee Scott	Officer	Jan 06 '26	Proposed Sale	76.95	1,340	103,110		Jan 06 04:33 PM
Boulding Mark Elliott	Officer	Jan 06 '26	Proposed Sale	76.95	1,739	133,812		Jan 06 04:25 PM
Gravier Pierre	Officer	Jan 06 '26	Proposed Sale	76.95	2,139	164,591		Jan 06 04:25 PM
Almstead Zheng Yang	Member of immediate family of	Jan 06 '26	Proposed Sale	76.95	54	4,155		Jan 06 04:24 PM
Pauwels Eric	Officer	Jan 06 '26	Proposed Sale	76.95	1,789	137,659		Jan 06 04:16 PM
Almstead Neil Gregory	Officer	Jan 06 '26	Proposed Sale	76.95	1,279	98,416		Jan 06 04:15 PM
Boulding Mark Elliott	Officer	Jan 05 '26	Proposed Sale	76.00	2,266	172,216		Jan 05 02:00 PM
Reeve Emma	Director	Jan 05 '26	Proposed Sale	76.00	734	55,784		Jan 05 11:02 AM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 30 '25	Sale	76.64	8,089	619,941	341,875	Jan 02 05:20 PM
STEELE GLENN JR MD PHD	Director	Jan 02 '26	Proposed Sale	76.35	12,000	916,200		Jan 02 12:37 PM
Klein Matthew B.	Officer	Dec 30 '25	Proposed Sale	76.64	8,089	619,922		Dec 30 03:09 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Option Exercise	65.15	20,508	1,336,186	90,178	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 19 '25	Sale	77.26	20,508	1,584,350	70,373	Dec 23 05:15 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Option Exercise	62.06	40,290	2,500,282	105,734	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Option Exercise	62.69	3,202	200,732	73,204	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 17 '25	Sale	75.43	40,290	3,038,924	70,373	Dec 19 05:20 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Dec 18 '25	Sale	75.06	3,202	240,351	70,373	Dec 19 05:20 PM
Pauwels Eric	Officer	Dec 19 '25	Proposed Sale	77.26	20,508	1,584,388		Dec 19 04:18 PM
SCHMERTZLER MICHAEL	Director	Dec 16 '25	Option Exercise	30.86	24,000	740,640	155,266	Dec 18 05:20 PM
Pauwels Eric	Officer	Dec 18 '25	Proposed Sale	75.06	3,202	240,354		Dec 18 04:30 PM
Pauwels Eric	Officer	Dec 17 '25	Proposed Sale	75.42	40,290	3,038,756		Dec 17 04:30 PM
Reeve Emma	Director	Dec 03 '25	Option Exercise	46.54	733	34,114	7,399	Dec 05 05:20 PM
Reeve Emma	Director	Dec 03 '25	Sale	78.62	733	57,628	6,666	Dec 05 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 02 '25	Sale	79.07	3,428	271,052	349,964	Dec 03 05:20 PM
Reeve Emma	Director	Dec 03 '25	Proposed Sale	78.62	733	57,628		Dec 03 10:40 AM
Klein Matthew B.	Officer	Dec 02 '25	Proposed Sale	79.07	3,428	271,063		Dec 02 03:11 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Option Exercise	30.75	71,928	2,211,679	148,249	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 25 '25	Sale	83.44	71,928	6,001,932	100,625	Nov 26 05:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Option Exercise	30.23	35,572	1,075,296	121,831	Nov 26 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Nov 24 '25	Sale	80.18	35,572	2,852,031	100,625	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Option Exercise	15.00	14,199	213,017	25,351	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Option Exercise	14.73	11,801	173,883	23,551	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 25 '25	Sale	83.55	14,199	1,186,282	17,451	Nov 26 05:20 PM
Jacobson Allan Steven	Director	Nov 24 '25	Sale	80.14	11,801	945,736	17,451	Nov 26 05:20 PM
Reeve Emma	Director	Nov 21 '25	Option Exercise	51.16	10,000	511,600	16,666	Nov 25 05:20 PM
Reeve Emma	Director	Nov 21 '25	Sale	79.50	10,000	795,000	6,666	Nov 25 05:20 PM
Almstead Neil Gregory	Officer	Nov 25 '25	Proposed Sale	83.44	71,928	6,001,523		Nov 25 05:18 PM
Jacobson Allan Steven	Director	Nov 25 '25	Proposed Sale	83.45	14,199	1,184,975		Nov 25 04:23 PM
Almstead Neil Gregory	Officer	Nov 24 '25	Proposed Sale	80.18	35,572	2,852,154		Nov 24 04:34 PM
Jacobson Allan Steven	Director	Nov 24 '25	Proposed Sale	80.14	11,801	945,753		Nov 24 04:29 PM
Reeve Emma	Director	Nov 21 '25	Proposed Sale	79.50	10,000	795,000		Nov 21 04:38 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Option Exercise	25.69	2,812	72,240	106,713	Nov 19 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Nov 17 '25	Sale	75.99	2,812	213,687	103,901	Nov 19 05:20 PM
Boulding Mark Elliott	Officer	Nov 17 '25	Proposed Sale	75.01	2,812	210,928		Nov 17 10:06 AM
Reeve Emma	Director	Nov 12 '25	Option Exercise	46.54	7,333	341,278	13,999	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Sale	74.50	7,333	546,308	6,666	Nov 14 05:20 PM
Reeve Emma	Director	Nov 12 '25	Proposed Sale	74.50	7,333	546,308		Nov 12 11:58 AM
PTC Therapeutics, Inc.	Affiliate of director	Nov 12 '25	Proposed Sale	16.53	894,578	14,787,374		Nov 12 11:45 AM
Reeve Emma	Director	Oct 30 '25	Option Exercise	38.10	12,000	457,200	18,666	Oct 31 05:20 PM
Reeve Emma	Director	Oct 30 '25	Sale	69.50	15,666	1,088,787	6,666	Oct 31 05:20 PM
Reeve Emma	Director	Oct 30 '25	Proposed Sale	69.50	15,666	1,088,787		Oct 30 12:24 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Oct 07 '25	Option Exercise	38.10	3,375	128,588	107,276	Oct 09 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Oct 07 '25	Sale	63.43	3,375	214,091	103,901	Oct 09 05:20 PM
Reeve Emma	Director	Oct 03 '25	Option Exercise	35.73	25,562	913,334	20,332	Oct 07 05:20 PM
Reeve Emma	Director	Oct 03 '25	Sale	65.96	25,562	1,686,024	10,332	Oct 07 05:20 PM
Jacobson Allan Steven	Director	Oct 03 '25	Option Exercise	30.86	12,000	370,320	29,451	Oct 07 05:20 PM
Jacobson Allan Steven	Director	Oct 03 '25	Sale	65.00	12,000	780,000	17,451	Oct 07 05:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTCT

PTC Therapeutics Inc

Upgrade your FINVIZ experience